Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Phillip Green

Pain Medicine Memphis, TN Medical Doctor

NPI 1639175037 CMS profile 28462

6325 Humphreys Blvd, Memphis, TN 38120

Open in the dashboard

General payments

$34,390

325 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Phillip Green of Memphis, TN is reported in the CMS Open Payments database as having received $34,390 across 325 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,077 68
2024 General $1,092 26
2023 General $1,128 47
2022 General $3,803 64
2021 General $14,183 29
2020 General $6,892 25
2019 General $4,216 66

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Phillip Green
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Phillip Green were reported at $3,077. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Phillip Green Pain Medicine median Middle half National median
2019 $4,216 $498 $126–$1,682 $163
2020 $6,892 $284 $80–$910 $114
2021 $14,183 $399 $112–$1,219 $132
2022 $3,803 $455 $137–$1,484 $149
2023 $1,128 $484 $128–$1,495 $160
2024 $1,092 $498 $131–$1,540 $164
2025 $3,077 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $19,139 125 payments
  2. Medtronic USA, Inc. $7,980 79 payments
  3. Arthrex, Inc. $1,927 4 payments
  4. Abbott Laboratories $1,751 13 payments
  5. Gentleman Orthopedic Solutions $1,152 5 payments
  6. Kowa Pharmaceuticals America, Inc. $913 55 payments
  7. Curonix LLC $479 6 payments
  8. SI-BONE, Inc. $460 5 payments
  9. Boston Scientific Corporation $373 23 payments
  10. Avanos Medical $34 1 payment
  11. Other $183 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $19,653 7 payments
  2. Food and Beverage $7,506 295 payments
  3. Travel and Lodging $5,314 21 payments
  4. Education $1,918 2 payments
Products named General payments · program years 2019–2025
  1. SYNCHROMED Drug Infusion Systems $6,255 9 payments
  2. ADAPTIVESTIM $3,675 1 payment
  3. INTELLIS $3,513 48 payments
  4. VANTA ADAPTIVESTIM $2,818 13 payments
  5. RESTORE $2,598 1 payment
  6. PROCLAIM $1,746 12 payments
  7. INTELLIS ADAPTIVESTIM $1,573 58 payments
  8. SYNCHROMED Drug Infusion Systems $567 21 payments
  9. PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A $479 6 payments
  10. Seglentis $472 28 payments
  11. Other $2,460 114 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

397

Median for Anesthesiology: 322

Drug cost

$3,980

Median for Anesthesiology: $8,738

Branded share of claims

39%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 96 $848
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 42 $663
Morphine Sulfate Er Morphine Sulfate Brand 17 $604
Gabapentin Generic 75 $555
Methadone Hcl Generic 12 $346
Oxycodone Hcl Generic 19 $283
Tramadol Hcl Generic 75 $277
Pregabalin Generic 13 $180
Tizanidine Hcl Generic 16 $134
Meloxicam Generic 14 $66

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$224,020

Of which drugs: $139

Medicare patients

460

Average age 72

Services billed

4,606

301 women, 159 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 37%
Depression 37%
Ischemic heart disease 36%
Chronic kidney disease 25%
COPD 24%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 157 1,192 $104
Injection, midazolam hydrochloride, per 1 mg J2250 Office 19 54 $6

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

325 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record